America's Largest Orphan Drug & Rare Disease Event

Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund ...

Federico Goodsaid is a regulatory strategy consultant at Regulatory Pathfinders and Ariana Data Intelligence. He was CEO of MBQ-Pharma, a biotech company licensing IP developed at the University of Puerto Rico. The goal of MBQ Pharma is to commercialize anticancer drugs developed through this...

Rob, a former All-American punter at Syracuse. In 2010, during his senior season, he was diagnosed with a rare form of brain cancer. His treatment lasted 16 months, ending his NFL aspirations. A Syracuse University graduate, Rob earned a B.S. from the Whitman School of Management and a Master’s in ...

Dr. Devyn Smith brings significant cell and gene therapy development and platform expertise from his 20+ year career. Devyn joined Arbor Biotechnologies as Chief Executive Officer on April 27, 2021 after concluding his role as Chief Operating Officer of Sigilon Therapeutics. Prior to...

With a first degree in Biochemistry and Pharmacology, and a Ph.D. focusing on drug metabolism and Pharmacokinetics, Graeme has worked in the areas of Drug Safety and Medical services for over 35 years. Having worked as a Head of Global Pharmacovigilance for a multi-national innovator Company and EU ...

Jessica Cerullo is a dedicated and passionate Senior Director of Patient Advocacy & Disease States Initiatives at Pierre Fabre Pharmaceuticals. With over a decade of experience in the pharmaceutical industry, Jessica has established herself as a leader in advocating for patients with rare...

Amanda Forys is Managing Partner at Magnolia Market Access. Her consulting and manufacturer experience has covered a wide range of commercialization topics, including health policy, pricing and rebating, coding, coverage and reimbursement, health economics, budget impact modeling, patient...

I am the Founder & CEO of Biovance Consulting LLC, and a physician-executive with a unique blend of medical, commercial, and operational leadership. I specialize in helping high-growth biopharma companies focused on bringing Rare Disease companies bring life-altering therapies to market with...

Dr. Paul August has dedicated his career to transforming scientific discovery into tangible hope for patients battling rare and neurological diseases.  Dr. August currently serves as Chief Scientific Officer at ReviR Therapeutics, where he spearheads innovative research programs for devastating...

Michael was first introduced to rare diseases while a student in college when his father was diagnosed with a rare form of cancer. As with many rare families, this experience launched him on an odyssey for answers. He began his career with Senator Orrin Hatch, Republican of Utah where he developed...

Will Greene is a rare disease researcher and patient advocate based in the San Francisco Bay Area. He serves on the board of the Foundation for Prader-Willi Research (FPWR), where he provides strategic oversight and supports efforts to accelerate research, advocacy, and community engagement. He is...

Having had a child with primary immunodeficiency (PI), I invested in the medical profession and trained to become a medical assistant at the Ohio Institute of Health Careers. My focus has always been on helping patients and guiding them to needed resources. I spent a decade in the PI consumer...

Yael Weiss Is currently CEO of Mahzi Therapeutics, a company focused on the development of therapies for ultra-rare genetic neurodevelopmental disorders. Mahzi works closely with patient foundations to support their journey towards drug development and bring programs into Mahzi once pre-clinical...